Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of F027 (Semaglutide Biosimilar) vs Ozempic in Type 2 Diabetes
NCT07046273Phase 3Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Peptides
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Shandong New Time Pharmaceutical. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07046273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046273.